MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Dollar
Positive Cash Flow Breakdown
Stock-based compensation expense...
Stock-based compensation expense
Prepaid expenses
Net proceeds from sale of common...
Negative Cash Flow Breakdown
Proceeds from teli contribution,...
Repayment of payable to related ...
Trade accounts payable and accru...
Repayments on insurance loan pay...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-1,721,528
-990,947
-2,061,193
-8,352,012
Stock-based compensation expense
198,734
39,803
-7,949
-741,858
Issuance of common stock for services
-
-
0
840,000
Stock-based compensation expense stock option modification
587,737
-
-
-
Prepaid expenses
-33,406
174,335
-18,129
-2,468
Trade accounts payable and accrued liabilities
-84,089
-257,153
207,394
74,419
Due to related parties
-
26,592
224,802
-
Accrued compensation - officer
0
-417,470
417,470
-
Net cash used in operating activities
-1,012,332
-1,773,510
-1,201,347
-927,264
Repayment to officer
0
-155,518
155,518
-
Proceeds from issuance of insurance loan payable
0
224,789
-
-
Repayments on insurance loan payable
66,496
21,920
-
-
Proceeds from teli contribution, related party
-2,000,000
-
-
3,000,000
Proceeds from sale of common stock, related party
-
-
3,000,000
-
Repayment of payable to related party
317,708
-
-
-
Proceeds from sale of common stock
-
-
-
4,502,239
Net proceeds from sale of common stock
-
-
6,553,209
-
Net proceeds from sale of common stock in atm
6,311
-
-
-
Net cash provided by financing activities
622,107
47,351
1,158,719
7,502,239
Net change in cash
-390,225
-1,726,159
-42,628
6,574,975
Cash, beginning of period
5,560,511
7,286,670
7,329,298
1,266,131
Cash, end of period
5,170,286
5,560,511
7,286,670
7,329,298
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
something is missing
$3,000,000
Net proceeds from
sale of common stock...
$6,311
Net cash provided by
financing activities
$622,107
(-40.63%↓ Y/Y)
Canceled cashflow
$2,384,204
Net change in cash
-$390,225
(23.76%↑ Y/Y)
Canceled cashflow
$622,107
Stock-based compensation
expense stock option...
$587,737
Stock-based compensation
expense
$198,734
(-96.71%↓ Y/Y)
Prepaid expenses
-$33,406
(-291.83%↓ Y/Y)
Proceeds from teli
contribution, related party
-$2,000,000
Repayment of payable to
related party
$317,708
Repayments on insurance
loan payable
$66,496
Net cash used in
operating activities
-$1,012,332
(35.09%↑ Y/Y)
Canceled cashflow
$819,877
Net loss
-$1,721,528
Trade accounts
payable and accrued...
-$84,089
(74.72%↑ Y/Y)
Buy us a coffee
Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc. (TELO)